Clinical Trial: Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Press/Media

Period16 Dec 2019

Media coverage

1

Media coverage

  • TitleClinical Trial: Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
    Media name/outletHealth Daily Digest (Ht Media)
    Country/TerritoryIndia
    Date16/12/19
    PersonsThomas Marron
View all 1
View less